IMPORTANT SAFETY INFORMATION: Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.
Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg).Please see additional Important Safety Information below.
For your patients with overactive bladder (OAB)
MYRBETRIQ is a β3-adrenergic agonist indicated for patients with OAB symptoms of urge urinary incontinence, urgency, and urinary frequency1
It may be time to take another look at OAB treatment with MYRBETRIQ
*Not a guarantee of coverage. Please verify coverage and updated information with the plan sponsors. Information subject to change without notice.
†By total Commercial covered lives (162,655,877); Plan types: Commerical, Commercial (BCBS), Employer, HIX, PBM, Union. Source: Fingertip Formulary, as of July 2015.